Study summary

Amivantamab plus lazertinib helped people live longer than osimertinib

MARIPOSA trial (amivantamab plus lazertinib) · 858 people in the two main groups, phase 3 · Published October 2025, New England Journal of Medicine

60%alive at 3 years, vs 51% with osimertinib

What was tested

Amivantamab, an antibody that blocks both EGFR and MET, plus lazertinib, an EGFR pill, against osimertinib alone as first treatment for advanced EGFR-mutated lung cancer.

What they found

What it means

A second first-line option that adds survival, at the cost of more side effects and regular infusions.

N Engl J Med, via PubMed ↗ Trial record NCT04487080 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.